CAMP4 Therapeutics Corp. (CAMP), a clinical-stage biopharmaceutical company, Thursday, provided an update on its lead investigational asset CMP-CPS-001.
CMP-CPS-001 is an antisense oligonucleotide therapeutic candidate for treating Urea Cycle Disorders (UCD), a rare genetic metabolic disorder that prevents the body from safely removing ammonia.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.